IL1A and pericarditis: At present, suitable candidates for IL-1 blocker administration include patients with glucocorticoid-dependent colchicine pericarditis with frequent (≥2) relapses who depict an autoinflammatory phenotype (namely CRP elevation, fever, and pleuropulmonary involvement).